机译:转移肾细胞癌接受第一线靶向治疗的患者的可变条件存活率和相关预后剂
Department of Urology Samsung Medical Center Sungkyunkwan University School of Medicine;
Department of Urology Korea University College of Medicine;
Department of Urology Seoul National University Hospital;
Department of Urology Chonnam National University Hwasun Hospital;
Department of Urology Asan Medical Center;
Department of Urology Seoul St. Mary's Hospital;
Department of Urology Seoul National University Hospital;
Department of Urology National Cancer Center;
Department of Urology Samsung Medical Center Sungkyunkwan University School of Medicine;
Department of Urology Samsung Medical Center Sungkyunkwan University School of Medicine;
Department of Urology Samsung Medical Center Sungkyunkwan University School of Medicine;
Division of Hematology-Oncology Department of Internal Medicine Samsung Medical Center;
Department of Urology Samsung Medical Center Sungkyunkwan University School of Medicine;
Department of Urology Samsung Medical Center Sungkyunkwan University School of Medicine;
Department of Urology Kangbuk Samsung Hospital;
Department of Urology Samsung Medical Center Sungkyunkwan University School of Medicine;
kidney; carcinoma; renal cell; neoplasm metastasis; mortality; protein-tyrosine kinases;
机译:转移肾细胞癌接受第一线靶向治疗的患者的可变条件存活率和相关预后剂
机译:一项针对VEGF的靶向治疗转移性肾细胞癌患者的条件生存:一项基于人群的研究
机译:在第一线酪氨酸激酶抑制剂后进展时间预测接受二线分子靶向治疗的转移性肾细胞癌患者的存活
机译:何时治疗转移性肾细胞癌的组合,全身治疗,以及在转移性肾癌中的活跃监测
机译:用于诊断转移性肾细胞癌的患者的基于权利要求的基于权利要求的方法论方法
机译:患有与血管内皮生长因子靶向疗法治疗的转移性肾细胞癌生存的条件:人口为基础的研究
机译:MP03-08靶向治疗治疗转移性肾细胞癌患者现代存活预测综合分析与验证